Core Insights - The company reported positive results for the fourth quarter, with revenue and EBITDA aligning with expectations [1] - Organic software revenue for 2025 achieved a growth rate of 7%, meeting the original plan [1] - The EBITDA margin reached 32%, which was at the high end of the initial guidance, indicating strong profitability [1] - However, there was a noted deceleration in software bookings and trends as the year concluded [1]

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that Novari Health (“Novari”), a VitalHub company, and Niagara Health are building upon an existing partnership by implementing Novari’s Medical Imaging Requisition Management (“MIRM”) and eRequest referral management technologies across the Niagara Region. Novari’s MIRM and eRequest technologies will be implemented at all of Niagara Health’s sites including Fort Erie Complex and ...

Core Insights - Waystar has expanded its collaboration with Google Cloud to enhance its AI capabilities, aiming to create an autonomous revenue cycle in healthcare [1] - The partnership leverages Google Cloud's Gemini models and infrastructure to improve revenue cycle workflows and accelerate innovation [1] - Waystar's AI platform has already prevented over $15 billion in denied claims and reduced denial appeal time by 90% [1] Company Overview - Waystar is a leading provider of healthcare payment software, serving over 30,000 clients and more than one million distinct providers [1] - The company processes over 7.5 billion healthcare payment transactions annually, amounting to over $2.4 trillion in gross claims [1] - Waystar's mission is to simplify healthcare payments, allowing providers to focus on patient care and financial performance [2] AI and Technology Advancements - The integration of generative and agentic AI into Waystar's platform aims to create a self-learning revenue cycle that continuously improves payment processes [1] - The collaboration with Google Cloud is expected to unlock new use cases for AI in healthcare, enhancing the efficiency of claims management [1] - Waystar has introduced the first proprietary AI agent within revenue cycle workflows, moving from insights to automated actions [1]

Core Insights - Small-cap stocks are gaining renewed investor interest in 2026 as capital shifts away from mega-cap stocks, with Goldman Sachs highlighting potential opportunities among AI ecosystem suppliers [2][3] - The easing rate environment is expected to benefit small-cap stocks, with anticipated rate cuts and accelerating earnings providing compelling investment opportunities [3] - The S&P 500 index has remained flat year-to-date, indicating a shift in the AI narrative and a drag from large-cap tech stocks, while the equal-weight S&P 500 shows positive performance [4][5] Company Summaries CeriBell, Inc. (NASDAQ:CBLL) - CeriBell reported Q4 2025 sales of $24.8 million, a 34% increase from the previous year, driven by growth in new and existing accounts [11] - The company achieved a gross profit of $21.6 million with a gross margin of 87%, but reported a net loss of $13.5 million [11] - For the full year, total income reached $89.1 million, up 36% from 2024, with a gross margin of 88% and expectations of $111 million to $115 million in sales for 2026 [12][13] HealthStream, Inc. (NASDAQ:HSTM) - HealthStream's Q4 2025 revenue was $79.7 million, a 7.4% increase year-over-year, with operational income impacted by a stock-based compensation charge [15] - The company reported a full-year revenue of $304.1 million, up 4.3%, and adjusted EBITDA growth of 7.5% to $71.8 million [16] - HealthStream is focused on providing healthcare workforce solutions, enhancing staff competency and regulatory adherence through its cloud-based platforms [17]

Core Insights - Comprehensive Healthcare Systems Inc. (CHS) is hosting a webinar on February 25, 2026, to discuss its transformation into a scalable, high-margin AI-enabled healthcare SaaS platform [1][2] Company Overview - CHS is a leader in healthcare benefits administration software and services, focusing on digitizing healthcare with its proprietary Novus 360 Healthcare Welfare, Benefits and Pension Administration (HWBA) platform [2][6] - The company supports over one million lives annually and has processed more than $1.8 billion in healthcare claims, generating over 90% recurring revenue with a customer retention rate exceeding 95% [3] Market Position - Operating in a $4-6 billion U.S. healthcare benefits administration software market, CHS is currently valued at less than 1x forward revenue, indicating a de-risked platform with potential for margin expansion and valuation re-rating [4] Growth Potential - CHS has approximately C$35 million (US$25 million) in signed contracts, including a significant multi-year agreement with Amalgamated Life Insurance Company, positioning the company to target US$100 million in signed contracts by 2028 [3]

Financial Data and Key Metrics Changes - In Q4, the company achieved $63.4 million in total revenue, reflecting a 17% year-over-year growth, with gross margin reaching a record 73.3% [20][24] - Operating income for Q4 was $2.3 million, marking an improvement of over $500,000 compared to Q4 2024, resulting in an operating margin of 3.6% [23][30] - For the full year 2025, total revenue grew 17% to $239 million, with gross margin expanding to 72.7%, up 80 basis points from the previous year [30] Business Line Data and Key Metrics Changes - Weave Payments grew at more than twice the rate of total revenue in 2025, driven by new capabilities like automated payment reminders and bulk collections [16] - The specialty medical vertical became the second-largest vertical by location count, with significant growth in Q4 [16] Market Data and Key Metrics Changes - The company is in fewer than 15% of U.S. dental locations, indicating substantial growth potential in the dental market [19] - Specialty medical, which currently holds about 1% market share, is expected to be a significant growth area due to the introduction of AI-powered solutions [20] Company Strategy and Development Direction - The company aims to enhance patient experiences through a unified platform that reduces administrative burdens for healthcare professionals [5][6] - The acquisition of TrueLark is seen as a foundational step in expanding AI Receptionist capabilities, addressing staffing challenges in practices [13][19] - The company plans to roll out an omnichannel AI Receptionist in 2026, which will allow practices to manage patient interactions across various channels [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of revenue growth and margin expansion, emphasizing the importance of AI in enhancing operational efficiency [17][30] - The company anticipates continued strong growth in specialty medical and mid-market sectors, supported by recent investments in sales and marketing [22][31] Other Important Information - The company ended Q4 with $81.7 million in cash and short-term investments, reflecting strong liquidity [23] - The net revenue retention rate in Q4 was 93%, with gross revenue retention at 89%, indicating strong customer retention despite some challenges in newer verticals [24][28] Q&A Session Summary Question: Can you elaborate on the CareCredit integration? - The CareCredit partnership opens new avenues for capturing volumes that would otherwise flow through CareCredit, enhancing the payment solution's attractiveness [35][36] Question: What are your expectations for growth rates across different subverticals in 2026? - Management anticipates strong growth across specialty medical and mid-market sectors, with specialty medical expected to lead due to recent marketing efforts [37][38] Question: How do you plan to monetize the new AI capabilities? - The company is exploring whether to price new functionalities as additional modules or include them in existing bundles, confident in the ability to monetize the AI omnichannel receptionist [42][43] Question: Have churn rates stabilized in specialty medical cohorts? - Churn rates have shown improvement in Q4, returning to historical levels, with ongoing integrations expected to further enhance retention [44][45] Question: What are the investment priorities for the coming year? - Investment priorities include product and engineering, particularly in enhancing AI capabilities, as well as adjustments to the go-to-market strategy for efficiency [52][54] Question: How does Weave differentiate its AI capabilities from competitors? - Weave's unique advantages include ownership of the telephony stack, deep industry-specific workflows, and the ability to retain context across various patient interactions [56][58]

Financial Data and Key Metrics Changes - In Q4 2025, Weave Communications achieved a revenue growth of 17% year-over-year, with total revenue reaching $63.4 million [22] - Gross margin expanded to a record 73.3%, reflecting a year-over-year improvement of 70 basis points [22] - Operating income for Q4 was $2.3 million, marking an operating margin of 3.6%, which is a 30 basis point improvement from the previous year [25] - For the full year 2025, total revenue grew 17% to $239 million, and gross margin for the year expanded to 72.7%, up 80 basis points from the prior year [32] Business Line Data and Key Metrics Changes - Weave Payments grew at more than twice the rate of total revenue in 2025, driven by new capabilities like automated payment reminders and bulk collections [18] - The specialty medical vertical became the second-largest vertical by location count, with significant growth in Q4 [18] - The acquisition of TrueLark added AI receptionist capabilities, enhancing the product offering and expanding the total addressable market by approximately $7 billion to an estimated $22 billion [21] Market Data and Key Metrics Changes - Weave has been endorsed by the American Dental Association as its exclusive patient engagement solution, providing access to 160,000 members [22] - The company is in the early stages of penetration in the specialty medical market, currently holding roughly 1% market share [22] Company Strategy and Development Direction - The company aims to leverage AI to reduce administrative burdens for healthcare professionals, enhancing patient care and operational efficiency [6][10] - Weave plans to roll out an omni-channel AI receptionist across all vertical markets in 2026, which will allow practices to handle calls 24/7 [16] - The focus is on integrating AI capabilities into existing workflows to create a seamless experience for healthcare providers [60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of revenue growth and margin expansion, highlighting the importance of customer success in driving long-term value [19] - The company anticipates continued strong growth in specialty medical and mid-market sectors, supported by recent investments in sales and marketing [40] - Management expects total revenue for Q1 2026 to be in the range of $64.2 million to $64.8 million, with an operating income of $1 million to $2 million [33] Other Important Information - The company ended Q4 with $81.7 million in cash and short-term investments, reflecting strong liquidity [25] - Free cash flow for the full year was $12.9 million, representing a 24% year-over-year growth [26] Q&A Session Summary Question: Can you talk about the CareCredit integration? - The CareCredit partnership opens avenues to capture volumes that would otherwise flow through CareCredit, enhancing the payment solution for practices [38] Question: What are your expectations for growth rates across different subverticals in 2026? - Management anticipates strong growth across specialty medical and mid-market sectors, with specialty medical expected to be the fastest-growing segment [40][41] Question: How do you plan to capture the value delivered by new AI capabilities? - The company is exploring monetization strategies for the AI receptionist, considering whether to price it as an additional module or include it in a bundle [45] Question: How do you see the impact of new products like TrueLark on net revenue retention? - The growth from the AI receptionist is expected to be more pronounced in the second half of 2026, with significant upsell opportunities anticipated [72]

Summary of Vitalhub FY Conference Call (January 15, 2026) Company Overview - **Company Name**: Vitalhub - **Ticker Symbols**: VHIBF (OTCPK, U.S.), VHI (TSX, Canada) - **Industry**: Healthcare IT Software - **Market Focus**: Government-funded healthcare systems in Canada, UK, Australia, Europe, and the Middle East - **Growth Strategy**: Combination of organic growth and strategic acquisitions, with 23 acquisitions completed to date [4][5] Core Business and Solutions - **Primary Focus**: Patient flow-based solutions that integrate various healthcare pathways, including hospitals, long-term care, and home care [6] - **Customer Base**: - 35% of revenue from Canadian operations - 33% from the UK - Remaining revenue from Australia, the Middle East, and Europe [8] - **Sales Model**: Direct sales with some partnerships for advisory services; contracts are typically long-term, averaging 5-10 years [10][12] Financial Performance - **Annual Recurring Revenue (ARR)**: Approximately CAD 94 million, with 80% of business being recurring [20] - **Cash Position**: CAD 120 million in cash, no debt on the balance sheet [20] - **Gross Margin**: Typically around 80%-81% [20] - **Adjusted EBITDA Target**: Aiming for 25%-30% with organic growth of 10%-15% [20] Growth Drivers - **Organic Growth**: Driven by product expansion, pricing opportunities, and cross-selling among existing customers [16] - **M&A Strategy**: Focus on acquiring financially healthy companies that can be integrated into Vitalhub's existing operations; emphasis on technology compatibility and potential for innovation [17][18] Future Outlook - **2026 Goals**: - Continue with selective acquisitions, aiming for 3-4 per year - Improve financial metrics post-acquisition to align with the Rule of 40 [22][23] - Focus on integrating larger acquisitions and enhancing operational structures [23] - **AI Integration**: Plans to leverage AI to enhance product offerings and increase ARR, with expectations for growth in 2026 and 2027 [25][26] Key Takeaways for Investors - Vitalhub presents a secure investment opportunity with a strong recurring revenue model and a solid cash position - The company is well-positioned to capitalize on AI advancements in healthcare solutions, which could drive future growth [25][26]

Group 1 - Waystar Holding Corp. (NASDAQ:WAY) is considered a promising mid-cap healthcare stock with a current price target of $41, indicating a potential upside of nearly 25% for investors [1][2] - The company's growth prospects are bolstered by its strategic focus on AI-enabled automation in revenue cycle management, which is expected to enhance efficiency and cost-effectiveness [2] - Waystar's acquisition of Iodine Software is part of its inorganic growth strategy, aimed at expanding its addressable market and improving client retention through cross-selling opportunities [2] Group 2 - Market sentiment towards Waystar is highly positive, with 16 out of 17 analysts giving a Buy rating, resulting in an estimated 1-year average price target of $48.44, implying a 47.5% upside from the current level [3] - Waystar offers a comprehensive cloud-based software platform for payment processing in the healthcare industry, covering functions such as payment clearance, claims management, revenue capture, reporting, and analytics [4]

Core Viewpoint - The article discusses stocks categorized into "Naughty" and "Nice" lists based on the pricing of their options, highlighting those with inflated premiums to avoid and those with attractive pricing to consider for buying options. Naughty List - Stocks on the Naughty List have options prices that are significantly inflated, making them risky for trading calls or puts due to high premiums [2] - Oracle Corp. (NYSE:ORCL) has seen its implied volatility rise from 24 to 64, indicating overpriced options ahead of earnings [4] - Lululemon athletica Inc. (NASDAQ:LULU) shows options priced above normal, making it difficult to justify long calls or puts [5] - Paychex Inc. (NASDAQ:PAYX) has inflated options that do not align with its consistent performance, stacking odds against buyers [7] - Ciena Corp. (NYSE:CIEN) has overpriced options despite solid stock movement, making it a red flag for potential buyers [8] - FactSet Research Systems Inc. (NYSE:FDS) has options trading at rich premiums, affecting the risk-reward balance for traders [10] Nice List - Stocks on the Nice List have options trading at or near their lowest levels of the year, providing opportunities for buying time premium without overpaying [11] - Uber Technologies Inc. (NYSE:UBER) has seen its implied volatility drop from 80 to 30, making it an attractive option for bullish plays [12] - Rubrik Inc. (NYSE:RBRK) is trading at the bottom of its implied volatility range, presenting a good opportunity for call buying [13] - Tempus AI Inc. (NASDAQ:TEM) is also at low option premium levels, making it a smart choice for potential moves [14] - Ross Stores Inc. (NASDAQ:ROST) has equal high and low volatility levels, indicating a new low in options pricing, which could be favorable for long calls [15] - Ventas Inc. (NYSE:VTR) has dropped premiums near year-lows, making it an attractive option for buyers if a catalyst appears [16]